ipratropium bromide and albuterol Inhalation Spray for the
RIDGEFIELD, Conn., Oct. 7, 2011 /PRNewswire/ Boehringer Ingelheim Pharmaceuticals, Inc. Food and Drug Administration (FDA) has approved COMBIVENT RESPIMAT, a new, propellant free indiscount patagonia board shorts1haler product that uses a slow moving mist to deliver the same active ingredients of COMBIVENT Inhalation Aerosol in a metered dose inhaler (COMBIVENpatagonia better sweater navyT MDI). COMBIVENT RESPIMAT will be available for patients in mid 2012.
COMBIVENT RESPIMAT and COMBIVENT MDI are indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
In a 12 week, randomized, double blind, placebo and active controlled clinical trial, COMBIVENT RESPIMAT was shown to be clinically comparable to COMBIVENT MDI, in terms of FEV1. FEV1 is the maximal amount of air that can be forcefully exhaled in one second. In the study, treatment was administered to patients with COPD four times a day.
COMBIVENT MDI and COMBIVENT RESPIMAT are the only short acting bronchodilator products that offer two different medicines in a single inhaler. Clinical studies in patients with COPD have shown that the combination of ipratropium bromide and albuterol sulfate provides patients significantly greater improvement in lung fundiscount patagonia board shortsction than either component alone.
COMBIVENT RESPIMAT uses a new type of inhaler with a propellant free delivery mechanism to produce an slow moving mist. COMBIVENT RESPIMAT requires one inhalation per dose as compared to COMBIVENT MDI, which requires two inhalations per dose. COMBIVENT RESPIMAT also offers a dose indicator to inform patients of the amount of remaining medication in the inhaler.
COMBIVENT RESPIMAT is a testament to our company s dedication and focus on making meaningful developments in respiratory medicinpatagonia reviews down sweatere, said Greg Behar, President and CEO, Boehringer Ingelheim Pharmaceuticals, Inc. Leveraging our extensive respiratory therapeudiscount patagonia board shorts3tic experience and a long history of bringing innovadiscount patagonia board shorts2tive medicines to patients, we continue to expand our strong clinical program examining the potential of several late stage investigational compounds also delivered by the RESPIMAT inhaler.
COMBIVENT RESPIMAT was developed in response to the Montreal Protocol, an international treaty requiring the phase out of inhalers that use chlorofluorocarbons (CFCs) as propellants, such as COMBIVENT MDI. Cpatagonia az homes for saleOMBIVENT RESPIMAT uses a spring mechanism to release the medicatipatagonia better sweater jacket 6pmon, rather than a propellant, so it does not release CFCs or hydrofluoroalkane (HFA) propellants.
COMBIVENT RESPIMAT will be available to patients by prescription starting in mid 2012. To allow adequate time to transition, COMBIVENT MDI will be available until late 2013. As of January 1, 2014, COMBIVENT RESPIMAT will be the only COMBIVENT product available. We are committed to ensuring patients and healthcare professionals are accurately instructed on how to use the new type of inhaler, before COMBIVENT MDI is no longer on the market.
Chronic obstructive pulmonary disease (COPD) is also known as chronic bronchitis and emphysema. This disease makes it harder to breathe because less air is able to fmens patagonia alpine guide jacket black vw24low in and out of the lungs. As many as 24 million Americans may have COPD even those who haven t smoked in years and half of them remain undiagnosed. COPD is the fourth leading cause of death in the United States. It kills one person every four minutes and more people each year than breast cancer and diabetes combined.
Common symptoms of COPD include coughing, with or without mucus, or shortness of breath. These symptoms are often confused with normal signs of aging. As COPD progresses, symptoms tend to get worse and more damage occurs in the lungs. Breathing gradually becomes more difficult until people with COPD feel like they are inhaling and exhaling through a small straw.
About COMBIVENT (ipratropium bromide and apatagonia arizona for salelbuterol sulfate) Inhalation Aerosol (MDI) and COMBIVENT RESPIMAT (ipratropium bromide and albuterol) Inhalation Spray
COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT are indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator.
COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT are contraindicated in patients hypersensitive to any of components of the drug product or to atropine or its derivatives. COMBIVENT Inhalation Aerosol is also contraindicated in patients with a history of hypersensitivity to soya lecithin or related food prodpatagonia employment opportunities superioructs such as soybean and peanut.
COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT can produce paradoxical bronchospasm that can be life threatening. If it occurs, the COMBIVENT therapy should be discontinued immediately and alternative therapy instituted. If these symptoms occur, COMBIVENT may need to be discontinued. There is some evidence from post marketing data and published literature of rare occurrences of myocardial ischemia associated with albuterol. In addition, beta adrenergic agents have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. Therefore, COMBIVENT Inhalation Aerosol and COMBIVENT RESPIMAT should be used with caution in patients with cardiovascular disorders; especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Do Not Exceed Recommended Dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. Therefore, caution is advised when administering either medication to patients with prostatic hyperplasia or bladder neck obstruction. Ipratropium bromide, also may increase intraocular pressure. This may result in precipitation or worsening of narrow angle glaucoma. Therefore, COMBIVENT shouldiscount patagonia board shorts0d be used with caution in patients with narrow angle glaucoma.
Caution patients to avoid spraying the aerosol into their eyes and be advised that this may result in precipitation or worsening of narrow angle glaucoma, mydriasis, increased intraocular pressure, acute eye pain or discomfort, temporary blurring of vision, visual halos or colored images in association with red eyes from conjunctival and corneal congestion. Patients should also be advised that should any combination of these symptoms develop, they should consult their ppatagonia guide pants $5hysicpatagonia guide pants 60sian immediately. Boehringer Ingelheim has been a leader in developing therapies for chronic obstructive pulmonary disease for more than 20 years. More recently, the Company has also branched out into developing treatment options for asthma, lung cancer, IPF and other respiratory indications.
